

PERSONAL INFORMATION **Raul J. Andrade**

WORK EXPERIENCE

- January 1982-January 1992 **ASSISTANT PROFESSOR**
University of Malaga (Spain)
Department of Medicine.
University of Málaga. School of Medicine
- January 1992- Present **ASSOCIATE PROFESSOR**
University of Malaga (Spain)
Department of Medicine.
University of Málaga. School of Medicine
- June 2008- Present **FULL PROFESSOR**
University of Malaga (Spain)
Department of Medicine.
University of Málaga. School of Medicine
- January 1988-January 2010 **CONSULTANT PHYSICIAN IN HEPATOLOGY**
University Hospital of Málaga (Spain)
Service of Gastroenterology
University Hospital of Málaga
- January 2010- Present **DIRECTOR Service of Gastroenterology and Hepatology**
University Hospital of Málaga (Spain)
DIRECTOR
Service of Gastroenterology and Hepatology
University Hospital of Málaga

EDUCATION AND TRAINING

- 1979- **M.D. degree with full honours cum Laude.**
University of Málaga. (Spain)
School of Medicine
- 1983- **Certificate (specialist) in Internal Medicine.**
University of Málaga. School of Medicine (Spain)
Internal Medicine
- 1987- **Certificate (specialist) in Gastroenterology**
University of Málaga. School of Medicine (Spain)
Gastroenterology
- 1988- **Doctor in Medicine. Outstanding cum Laude.**
University of Málaga. School of Medicine (Spain)
Medicine

ADDITIONAL INFORMATION

Expertise Hepatotoxicity; Chronic viral hepatitis; Non alcoholic fatty liver disease

Publications MOST RELEVANT PUBLICATIONS:
HAO NIU, JIAYI MA, INMACULADA MEDINA-CALIZ, MERCEDES ROBLES-DIAZ, ELVIRA BONILLA-TOYOS, MARWAN GHABRIL, M^a ISABEL LUCENA, ISMAEL ALVAREZ-ALVAREZ, RAUL J. ANDRADE

Potential benefit and lack of serious risk from corticosteroids in drug-induced liver injury: An international, multicentre, propensity score-matched analysis

Alimentary Pharmacology & Therapeutics 2022 SENIOR

IN PRESS

IF 2021: 9.524 (D1: 17/279) PHARMACOLOGY & PHARMACY

<https://doi.org/10.1111/apt.17373>

FERNANDO BESSONE, MIREN GARCIA-CORTES, INMACULADA MEDINA-CALIZ, NELIA HERNANDEZ, RAYMUNDO PARANA, MANUEL MENDIZABAL, MARIA I SCHINONI, EZEQUIEL RIDRUEJO, VINICIUS NUNES, MIRTA PERALTA, GENARIO SANTOS, MARGARITA ANDERS, DANIELA CHIODI, MARTIN TAGLE, PEDRO MONTES, ENRIQUE CARRERA, MARCO ARRESE, M ISABEL LIZARZABAL, ISMAEL ALVAREZ-ALVAREZ, ESTEFANIA CABALLANO-INFANTES, HAO NIU, JOSE PINAZO, MARIA R CABELLO, M ISABEL LUCENA, RAUL J ANDRADE.

Herbal and Dietary Supplements-Induced Liver Injury in Latin America: Experience From the Latindili Network

Clin Gastroenterol Hepatol. 2022; 20(3):e548-e563 doi: 10.1016/j.cgh.2021.01.011. SENIOR AUTHOR

IF 2020: 11.382 (D1: 8/92)

EINAR S BJORNSSON, RAUL J ANDRADE

Case Reports. Review. Long-term sequelae of drug-induced liver injury

J Hepatol. 2022;76(2):435-445. doi: 10.1016/j.jhep.2021.10.011

IF 2021: 25.083 (D1: 5/93)

PMID: 34688732 CORRESPONDING AUTHOR

FERNANDO BESSONE, NELIA HERNANDEZ, MANUEL MENDIZABAL, EZEQUIEL RIDRUEJO, GISELA GUALANO, EDUARDO FASSIO, MIRTA PERALTA, HUGO FAINBOIM, MARGARITA ANDERS, HUGO TANNO, FEDERICO TANNO, RAYMUNDO PARANA, INMACULADA MEDINA-CALIZ, MERCEDES ROBLES-DIAZ, ISMAEL ALVAREZ-ALVAREZ, HAO NIU, CAMILLA STEPHENS, LUIS COLOMBATO, MARCO ARRESE, M VIRGINIA REGGIARDO, SUZANE KIOKO ONO, FLAIR CARRILHO, M ISABEL LUCENA, RAUL J ANDRADE.

Serious liver injury induced by Nimesulide: an international collaboration study reporting 57 cases

Archives of Toxicology 2021; 95(4):1475-1487.

IF 2021: 6.168 (D1: 9/100). TOXICOLOGY SENIOR

PMID: 33759010 <https://doi.org/10.1007/s00204-021-03000-8>

Lucena MI, Sanabria J, Garcia-Cortes M, Stephens C, Andrade RJ. Review. Drug-induced liver injury in older people. Lancet Gastroenterol Hepatol. 2020;5(9):862-874. doi: 10.1016/S2468-1253(20)30006-6. PMID: 32818465. SENIOR

IF 2021: 45.042 (D1: 2/93).

CAMILLA STEPHENS, MERCEDES ROBLES-DIAZ, INMACULADA MEDINA-CALIZ, MIREN GARCIA-CORTES, AIDA ORTEGA-ALONSO, JUDITH SANABRIA-CABRERA, ANDRES GONZALEZ-JIMENEZ, ISMAEL ALVAREZ-ALVAREZ, MAHMOUD SLIM, MIGUEL JIMENEZ-PEREZ, ROCIO GONZALEZ-GRANDE, M CARMEN FERNANDEZ, MARTA CASADO, GERMAN SORIANO, EVA ROMAN, HACIBE HALLAL, MANUEL ROMERO-GOMEZ, AGUSTIN CASTIELLA, ISABEL CONDE, MARTIN PRIETO, JOSE MARIA MORENO-PLANAS, ALVARO GIRALDEZ, J MIGUEL MORENO-SANFIEL, NEIL KAPLOWITZ, M ISABEL LUCENA, RAUL J ANDRADE.

Comprehensive analysis and further insights gained from the long-term experience of the Spanish DILI Registry.

Journal of Hepatology 2021; 75(1):86-97. 10.1016/j.jhep.2021.01.029

IF 2020: 25.083 (D1: 2/92). SENIOR AUTHOR

M ISABEL LUCENA, JUDITH SANABRIA, MIREN GARCIA-CORTES, CAMILLA STEPHENS, RAUL J ANDRADE.

Review. Drug-Induced Liver Injury in the elderly.

Lancet Gastroenterology & Hepatology 2020; 5 (9): 862-874

[https://doi.org/10.1016/S2468-1253\(20\)30006-6](https://doi.org/10.1016/S2468-1253(20)30006-6)

IF 2020: 18.486 (D1: 5/92). SENIOR AUTHOR

ANDRADE RJ, CHALASANI N, BJORNSSON ES, SUZUKI A, KULLAK-UBLICK GA, WATKINS PB, DEVARBHAVI H, MERZ M, LUCENA MI, KAPLOWITZ N, AITHAL GP.

Review. Drug-induced liver injury.

Nat Rev Dis Primers. 2019; 5(1):58. doi: 10.1038/s41572-019-0105-0.

IF 2020: 52.329 (D1: 4/167). FIRST AUTHOR AND CORRESPONDING AUTHOR

ZOUBEK ME, GONZALEZ-JIMENEZ A, MEDINA-CALIZ I, ROBLES-DIAZ M, HERNANDEZ N, ROMERO-GÓMEZ M, BESSONE F, HALLAL H, CUBERO FJ, LUCENA MI, STEPHENS C, ANDRADE RJ.

High Prevalence of Ibuprofen Drug-Induced Liver Injury in Spanish and Latin-American Registries.

Clin Gastroenterol Hepatol. 2018; 16 (2):292-294. doi: 10.1016/j.cgh.2017.07.037.

IF 2020: 11.382. (D1: 8/92). SENIOR AUTHOR

CLINICAL PRACTICE GUIDELINES PANEL: CHAIR: RAUL J. ANDRADE; PANEL MEMBERS: GURUPRASAD P. AITHAL, EINAR S. BJORNSSON, NEIL KAPLOWITZ, GERD A. KULLAK-UBLICK, DOMINIQUE LARREY; EASL GOVERNING BOARD REPRESENTATIVE: TOM H. KARLSEN.

EASL Clinical Practice Guidelines: Drug-induced liver injury

European Association for the Study of the Liver.

<https://doi.org/10.1016/j.jhep.2019.02.014>

Journal of Hepatology 2019; 70: 1222-1261

IF 2020: 25.083 (D1: 2/92)

ZOUBEK ME, GONZALEZ-JIMENEZ A, MEDINA-CALIZ I, ROBLES-DIAZ M, HERNANDEZ N, ROMERO-GÓMEZ M, BESSONE F, HALLAL H, CUBERO FJ, LUCENA MI, STEPHENS C, ANDRADE RJ.

High Prevalence of Ibuprofen Drug-Induced Liver Injury in Spanish and Latin-American Registries.

Clin Gastroenterol Hepatol. 2018; 16 (2):292-294 doi: 10.1016/j.cgh.2017.07.037. SENIOR

IF 2021: 13.576 (D1: 7/93)

INMACULADA MEDINA-CALIZ, MIREN GARCIA-CORTES, ANDRES GONZALEZ-JIMENEZ, MARIA R. CABELLO, MERCEDES ROBLES-DIAZ, JUDITH SANABRIA-CABRERA, ROCIO SANJUAN-JIMENEZ, AIDA ORTEGA-ALONSO, BEATRIZ GARCIA-MUNOZ, INMACULADA MORENO, MIGUEL JIMENEZ-PEREZ, M CARMEN FERNANDEZ, PERE GINES, MARTIN PRIETO, ISABEL CONDE, HACIBE HALLAL, GERMAN SORIANO, EVA ROMAN, AGUSTIN CASTIELLA, ENCARNACION BLANCO-REINA, MARIA R. MONTES, MARTA QUIROS-CANO, FLORES MARTIN-REYES, M ISABEL LUCENA, RAUL J. ANDRADE, on behalf of the Spanish DILI Registry.

Herbal and dietary supplement-induced liver injury in the Spanish DILI Registry.

<https://doi.org/10.1016/j.cgh.2017.12.051>

Clinical Gastroenterology and Hepatology (CGH) 2018; 16: 1495-1502

IF 2021: 13.576 (D1: 7/93) SENIOR

Projects

RESEARCH SUPPORT:

International Competitive grants:

Programme: Horizon Europe Framework Programme (HORIZON)

Call: Staying healthy (Single stage, 2022) (HORIZON-HLTH-2022-STAYHLTH-02)

Project: 101095679

HALT-RONIN. "Discovering chronic inflammation biomarkers that define key stages in the Healthy-to-NASH (non-alcoholic steatohepatitis) transition to inform early prevention and treatment strategies".

Type of action: HORIZON-RIA HORIZON Research and Innovation Actions

Duration: 48 months

Start Date: 01.12.2022-30.11.2026

European Union, Horizon Europe-Health Cluster (HORIZON-HLTH-2022). Role: Work Package Leader.

IP: Raul J. Andrade.

SAS-FIMABIS: 556.160

Referencia interna: 00300000200100167

Codigo UE: 101095679

EASL Registry Research Grant Programme 2020

Title: "Checkpoint-inhibitor induced liver injury: The CHILI registry"

PI: Palak Trivedi. Collaborator: Raul J. Andrade

Funding Agency: European Association for the Study of the Liver (EASL)

Years: 2020-2022. Budget: 63,665

COST ACTION CA17112 - Prospective European Drug-Induced Liver Injury Network (PRO-EURO DILI NET)

PI: Raul J. Andrade. Co-IP: Guruprasal Aithal.

Funding agency: European Union (H2020)

Years: October 2018-October 2022. Budget: 102.000 / year

IMI2- Translational Safety Biomarker Pipeline (TransBioLine): Enabling development and implementation of novel safety biomarkers in clinical trials and diagnosis of disease.

International agreement UMA-SAS project H2020 JTI IMI TRANSBIOLINE 2019-2023

PI: Raul J. Andrade

Funding agency: European Union. Years: 2019-2013. Budget: 188.947,00

EASL Registry Research Grants Programme. Title: Creation of a European Prospective Drug-Induced Liver Injury Registry (Pro-Euro-DILI Registry).

Principal investigator: Raul J. Andrade

Researchers: University of Malaga (Spain): M^a Isabel Lucena, Stephens, Mercedes Robles-Diaz, Inmaculada Medina-Caliz; University of Nottingham, UK: Guru Aithal.

Collaborating centres: Landspítali University Hospital, Iceland: Einar Bjornsson; University Hospital of Santa Maria, Portugal: Helena Cortez-Pinto; University of Dundee, Scotland/UK: John Dillon.

Funding agency: European Association for the Study of the Liver (EASL)

Budget: 50.000 - Years: 2014-2015

SAFE-T Safer and faster Evidence Based Translation. SAFE-T INTERFACE EUROPE. Grant Agreement number 523 705.

Principal Investigator: Raul J. Andrade

Researchers: M^a Isabel Lucena, Camilla Stephens

Funding agency: INNOVATIVE. MEDICINES INITIATIVE. European Union.

Budget: 149.400 Years: 2011-2014

Research line: Metabolic syndrome and Liver diseases

Proyecto FLIP: Stop Fatty Liver Progression

Partner n° 12 - RTD Spain

PI: Manuel Romero-Gomez. Collaborators: Raul J Andrade, Miren Garcia Cortes, Inmaculada Moreno

Years: 01/01/2009-31/12/2013

Study title: "Oxidative Stress Mechanisms in Drug-Induced Liver Injury",. Collaborative work among Ibima-UMA Prof Christian Trautwein and Dr. Francisco Javier Cubero Department of Internal Medicine III: Gastroenterology, Metabolic Disorders and Intensive Care Unit; University Hospital and Medical Faculty of RWTH AACHEN University, Alemania. Doctoral thesis Miguel Zoubeck 2014.

Research proposal submitted in Sept 2014 to the FDA which includes the following collaborating centres:

1Division of Bioinformatics and Biostatistics, National Center for Toxicological Research, FDA.

2Director, Division of Gastroenterology, Department of Medicine, Central Arkansas Veterans Healthcare System (CAVHS)

3Division of Systems Biology, National Center for Toxicological Research, FDA.

4 Clinical Pharmacology Service. IBIMA, University of Malaga. Spain

5Office of Pharmacovigilance and Epidemiology, CDER/FDA

6Director, Office of Clinical Pharmacology, CDER/FDA

7Director UGC Gastroenterology, IBIMA-HUM, University of Malaga, Malaga, Spain

8Department of Information, University of Arkansas at Little Rock.

9Director, Office of Computational Science, Office of Translational Science, CDER.

Project title: Unraveling drug-patient interaction in Drug-Induced Liver Injury by translating genomics discoveries into a population perspective to complement the bench-to-bedside model of translation.

Principal investigator: Yuping Wang

Total proposed budget \$298,000

Funding period: March, 01, 2015- Feb, 28, 2017.

Co-Investigators: Ayako Suzuki², Joshua Kwekel³, Maribel Lucena⁴, John Senior⁵, Issam Zineh⁶, Raul J Andrade⁷, Michael Chung⁸, Gang Chen⁸, Lilliam A. Rosario⁹, Wen Zou¹, James Fuscoe³, William Mattes³, James Chen¹, Xiaowei Xu⁷, Weida Tong¹

Collaboration with Liverpool University. Centre for Drug Safety Sciences. Prof Kevin Park. Characterization of biomarker profiles in patient samples with DILI.

Collaboracion with Neil Kaplowitz and his center.

NEIL KAPLOWITZ, M.D. Professor and Chief Division of Gastroenterology Keck School of Medicine of USC University of Southern California 2011 Zonal Ave, HMR101 Los Angeles, CA 90033

National Competitive grants:

Novel Combo Assay for Early Detection of Drug Induced Liver Injury (DILI)

Entidades participantes. Programme: Eurostars. Code: E!114589 - LiverAce.

1. DESTINA Genomica S.L. - Spain. IPs: Dr Juan Jose Diaz Mochon & Dr Salvatore Pernagallo

2. Datamedrix GmbH - Austria. IP: Mr Andreas Redl MSc

3. AIT Austrian Institute Of Technology GmbH - Austria. IP: Dr Christa Nohammer

4. Universidad de Malaga IBIMA - Spain (subcontracted). IPs: Dra Maribel Lucena & Dr Raul Andrade Bellido

5. University of Edinburgh, Royal Infirmary of Edinburgh - UK (subcontracted). IP: Dr. James Dear.

Entidad financiadora: Centro para el Desarrollo Tecnologico Industrial (CDTI) en Espana y FFG Osterreichische Forschungsforderungsgesellschaft mbH en Austria.

Importe: 1,417,892

Ano: 15/05/2021. Duracion: 25 meses

Contrato Sara Borrell. Convocatoria 2020 de la Accion Estrategica en Salud 2017-2020.

IP: Raul J. Andrade. Contratado: Ismael Alvarez Alvarez.

Expediente: CD20/00083

Anos: 01.01.2021-31.12.2023 (3 anos). Importe: 80.598

Fondo de Investigacion Sanitaria PI21/01248.

Fenotipado y caracterizacion mecanistica de la lesion hepatica inducida por farmacos, la esteatosis inducida por farmacos y la enfermedad del higado graso asociado al metabolismo.

IP: Raul J. Andrade Bellido. Co-IP: Miren Garcia-Cortes.

Colaboradores: Rocio Gonzalez-Grande, Marina Villanueva Paz, Ismael Alvarez-Alvarez, Enrique del Campo Herrera, Antonio Segovia Zafra, Juan Pedro Toro Ortiz.

Anos: 2022-2024. Importe: 304.920,00

Contrato i-PFIS: doctorados IIS-empresa en ciencias y tecnologias de la salud de la convocatoria 2021 de la Accion Estrategica en Salud 2017 - 2020.

Expediente: IFI21/0034

CONTRATADO: Daniel Di Zeo

IP: Raul J. Andrade.

Entidad financiadora: Instituto de Salud Carlos III

Ano: 2021-2024. Importe: 89.900

Premio IBIMA-Divulga a las mejores publicaciones de la Convocatoria 2022 del Plan Propio del Instituto de Investigacion Biomedica de Malaga y Plataforma en Nanomedicina (IBIMA. Plataforma BIONAND)

Primer premio a la publicacion del grupo D-05 "Comprehensive analysis and insights gained from long-term experience of the Spanish DILI Registry".

PR_DIVULGA_01_2022. Autores: Stephens, C; Robles-Diaz, M; Medina-Caliz, I; Garcia-Cortes, M; Ortega-Alonso, A; Sanabria-Cabrera, J; Gonzalez-Jimenez, A; Alvarez-Alvarez, I; Slim, M; Jimenez-Perez, M; Gonzalez-Grande, R; Fernandez, MC; Casado, M; Soriano, G; Roman, E; Hallal, H; Romero-Gomez, M; Castiella, A; Conde, I; Prieto, M; Moreno-Planas, JM; Giraldez, A; Moreno-Sanfiel, JM; Kaplowitz, N; Lucena, MI; Andrade, R. Importe: 2.000

Fecha concesion: 13/10/2022

Title: Evaluation of comedication and trajectories diseases in the modulation of drug-induced liver damage. Code PI18/01804

Main researcher: Raul J. Andrade

Co-Investigators: Jessica Gasca Bellido, Inmaculada Medina Caliz, Aida Ortega Alonso, Judith Adriana Sanabria Cabrera, Fernando Moreno Jabato, Alejandro Jose Cueto Sanchez.

Funding agency: Carlos III Health Institute.

Budget: 58.987,50 . Years: 2019-2021

Title: Analysis of physico-chemical drug properties, host factors and their interaction in hepatotoxicity phenotype presentation and outcome. Code PI15/01440

Main researcher: Raul J. Andrade

Co-Investigators: Mercedes Robles-Diaz, Juan Antonio Garcia, Inmaculada Medina Caliz, Andres Gonzalez Jimenez, Aida Ortega Alonso, David Velazco Sanchez.

Funding agency: Carlos III Health Institute.

Budget: 70.180 . Years: 2016-2018

Title: Long Term study of patients with DILI to determine morbimortality and susceptibility to develop new DILI episodes. Code PI12/00620.

Principal Investigator: Raul J. Andrade

Co-Investigators: CARMEN FERNANDEZ SANCHEZ, MIREN GARCIA CORTES, MERCEDES ROBLES DIAZ, BEATRIZ GARCIA MUNOZ, INMACULADA MEDINA CALIZ, HACIBE HALLAL HACHEM, JOSE MARIA MORENO PLANAS.

Funding agency: Carlos III Health Institute. Budget: 35.500 , Years: 2013-2015

Title: Role of the genetic variability of drug-transporter genes ABCB4, ABCB11, ABCC2, ABCB1 AND SLCO1B1 in the susceptibility to develop drug-induced idiosyncratic liver injury and its clinical expression. Code FIS PS09/01384

Principal Investigator: Raul J Andrade.

Collaborating: Maria Cabello, Eugenia Ulzurrun, Mercedes Robles-Diaz, Esperanza Crespo, Miren Garcia-Cortes.

Funding agency: Carlos III Health Institute.

Budget: 69.575 , years: 2010-2012

Independent (non-commercial) Clinical Research Title: A phase IV, multicenter, randomized, double-blind, placebo-controlled study to evaluate efficacy and safety of Sorafenib in patients with hepatocellular carcinoma after radiological progression. Code PROYECTO DE INVESTIGACION CLINICA INDEPENDIENTE. EC11-185

Principal Investigator: Jose Luis Montero Alvarez

Collaborating: Raul J Andrade.

Funding Agency: Ministry of Health

Budget: 188.315,00 ; years 2012-2014

Non-commercial clinical research projects with human medicines. Code: EC08/00116

Principal investigator: Dra. E. Ocete Hita (H. Clinico S Cecilio, Granada)

Researchers: The Drs Lucena, Andrade, Salmeron, Gimenez (H.Torrecardenas) , Flores (H. Puerta del Mar), Ibarra (H. Reina Sofia), Monteruel (H. De Cruces), Martinon (HCU de Santiago), Del Castillo (HGU Gregorio Maranon) y Romero (HUVN).

Funding agency: Carlos III Health Institute.

Budget: 31.460 . Years: (2009-2011)

Independent clinical research EC07/90910

RISK OF HEPATOTOXICITY ASSOCIATED WITH TREATMENT OF TUBERCULOSIS INFECTION. PHARMACOECONOMIC EVALUATION OF THE HEPATOTOXICITY

Principal investigator: M. Isabel Lucena

Co-Investigators: Ketevan Patchkoria, Manuel Carnero, Jose Luis Velazco, Raquel Cueto, Francisco Martos, Antonio Garcia. Budget: 27.225 . Years: 2008-2009

Regional Competitive grants:

Integrated analysis of pharmacological properties, host factors, epigenetic profile and its interaction, on the clinical phenotype and severity of drug-induced liver injury.

PIs: Raul J. Andrade; Mercedes Robles-Diaz

Co-Investigators: Laura Sanz Villanueva, Andres Gonzalez-Jimenez, Judith Sanabria Cabrera, Rocio Sanjuan Jimenez, Jessica Gasca-Bellido.

Proyectos I+D+I - Programa Operativo FEDER Andalucía 2014-2020

Code: UMA18-FEDERJA-193

Funding agency: Andalusian Health Service.

Years: November 2019- November 2021. Budget: 28.650

Exosomes, the immune response and its modulation by the GUT microbiota in the identification of mechanistic and prognostic hepatotoxicity biomarkers.

PIs: M^a Isabel Lucena; Camilla Stephens.

Co-Investigators: M Garcia Cortes, M Robles Diaz, A Alonso Ortega, J Sanabria Cabrera, M Jimenez, R Andrade.

Convocatoria PAIDI 2018. Ayudas a proyectos de I+D+I Programa Operativo FEDER 2014-2020. Code: PY18-3364.

Funding agency: Andalusian Agency of Knowledge.

Years: 2020-2023 (36 months). Budget: 140.352

ANDALUSIAN NETWORK FOR THE STUDY OF THE LIVER DISEASES. AC-0073-2013.

Principal investigator: Raul J. Andrade

Co-Investigators: M. Isabel Lucena, Manuel Romero Gomez, Francisco CAbello-Ruiz Osuna, Miguel Jimenez Perez, Jose Maria Navarro Jarabo, Carmen Fernandez Sanchez)

Funding agency: Ministry of Health, Social Policy and Equality.

Amount: 101.000 - Years: 2014-2015

Investigation of associations between MHC alleles and the susceptibility to develop drug-induced liver injury. P10-CTS 6470.

Principal investigator: M^a Isabel Lucena;

Co-Investigators: Francisco Ruiz Cabello, Miguel Angel Lopez Nevot, Raul J. Andrade, Camilla Stephens, Yolanda Borraz, Eugenia Ulzurrun

Funding agency: Regional research project, Andalusian Health Service, 2010.

Amount: 143.755,75 - Years: 2011-2014.

I+D agreements with public organisms

CB07/04/2008. GRUPO DE HEPATOPATIAS ASOCIADAS A MEDICAMENTOS. CIBERehd (CENTRO DE INVESTIGACION BIOMEDICA EN RED (Networked Biomedical Research Center) DE ENFERMEDADES HEPATICAS Y DIGESTIVAS (Hepatic and Digestive Diseases))
www.ciberehd.org

Principal investigator: RAUL ANDRADE. Researchers: M ISABEL LUCENA

Funding agency: CIBERehd (Network-based biomedical research Centre)

Years: 2017-2021. Amount: 50.000

Year: 2016- Amount: 42.000

Year: 2015- Amount: 50.000

Year: 2014- Amount: 42.000

Year: 2013- Amount: 52.000

Year: 2012- Amount: 61.183

Year: 2011- Amount: 80.000

Year: 2010- Amount: 70.000

Year: 2009- Amount: 65.000

Collaboration Agreement between the Spanish Medicine Agency and the University of Malaga, through the Pharmacology & Medicine department for the study of Drug-Induced Liver Injury.

Principal investigators: M^a Isabel Lucena Gonzalez, Raul J Andrade Bellido

Funding agency: The Spanish Medicine Agency

Amount: 27.000 . Year: 2007

Amount: 27.000 . Year: 2008

Amount: 25.636 . Year: 2009

Amount: 21.122 - Years: 2010-11

Amount: 21.122 . Years: 2011-12

Amount: 50.820 . Years: 2013- 2015

Amount: 50.820. Years: 2016-2017.

Amount: 60.500. Years: 2018-2020

Amount: 60.500.Years: 2020-2022

RESEARCH PLAN. University of Malaga (vicerrector of scientific research) grant for the setting-up of a clinical trial network in DILI.

PI: M^a Isabel Lucena. Co-Investigators: Raul J. Andrade, Maria Cabello Porras, Inmaculada Bellido, Encarnacion Blanco Reina, Javier Perez-Frias, Ismael Alvarez-Alvarez, Judith Sanabria-Cabrera, Mercedes Robles-Diaz, Hao Niu, Miren Garcia-Cortes, Aida Ortega-Alonso, Guruprasad Aithal, Anna Licata, Einar Stefan Bjornsson, Gerd A. Kullak-Ublick.

Code: 2020/REGSED-8324

Year: 25/06/2020 - 25/06/2021. Budget: 4000

RESEARCH PLAN. University of Malaga (vicerrector of scientific research) grant for the organization of the "I Working groups meeting of the COST" in the University of Malaga.

Main researcher: M^a Isabel Lucena. Co-investigator: Raul J. Andrade.

Funding agency: University of Malaga.

Year: 2019. Amount: 4.000

RESEARCH PLAN. University of Malaga (vicerrector of scientific research) grant for the setting-up of the "Transbioline Registry"

Principal investigator: M. Isabel Lucena. Co-IP: Raul J. Andrade

Budget: 4.000 Year: 2018-2019

RESEARCH PLAN. University of Malaga (vicerrector of scientific research) grant for the organization of the 2nd Meeting CIOMS in Malaga. 14-15 November 2017.

Amount: 4.000 Year: 2017

RESEARCH PLAN. University of Malaga (vicerrector of scientific research) grant for the setting-up of thematic networks: "Prospective European Drug-Induced Liver Injury Registry (Pro-Euro DILI registry)"

Principal investigators: M. Isabel Lucena & Raul J. Andrade.

Budget: 4.000 Year: 2015

RESEARCH PLAN. University of Malaga (vicerrector of scientific research) grant for the setting-up of thematic networks: Regional network for the identification and characterization of hepatotoxicities.

Principal investigators: M. Isabel Lucena & Raul J. Andrade.

Funding agency: University of Malaga.

Budget: 4.000 Year: 2014.

RESEARCH PLAN. University of Malaga (vicerrector of scientific research) grant for the setting-up of thematic networks: "Drug-Induced Liver Injury".

Principal investigator: M. Isabel Lucena & Raul J. Andrade.

Funding agency: University of Malaga. Budget: 4.000 Year: 2013

AUIP grant (Iberoamerican Postgraduate University Association, AUIP) for the setting-up of an Ibero-American hepatotoxicity network. SLADILIN study Project as a research member of the AUIP.

Year: 2013- Amount: 1.500

RESEARCH PLAN. University of Malaga (vicerrector of scientific research) grant for the setting-up of thematic networks: Regional network for the identification and characterization of hepatotoxicities.

Principal investigator: M. Isabel Lucena & Raul J. Andrade.

Funding agency: University of Malaga.

Amount: 4.000 Year: 2014.

RESEARCH PLAN. University of Malaga (vicerrector of scientific research) grant for the setting-up of thematic networks: "Drug-Induced Liver Injury".

Principal investigator: M. Isabel Lucena & Raul J. Andrade.

Funding agency: University of Malaga.

Amount: 4.000 Year: 2013

PAIDI (Plan Andaluz de Investigacion). Research group: The Lipids and Atherosclerosis research unit (General pathology)". CTS-159

Principal investigator: Pedro Gonzalez Santos

Co-investigators: Raul J. Andrade,...

Funding agency: Economics, Innovation and Science regional Ministry.

Years: 1994-up to date

PRIVATE CONTRACTS, SCIENTIFIC SOCIETIES

Collaboration agreement between NOTTINGHAM UNIVERSITY HOSPITALS NHS TRUST, University of Nottingham, FIMABIS, IBIMA&PFIZER. Transfer of the Data and Material from "Pro-Euro-DILI Registry" and "NASH" to Pfizer.

Project: Assessment of novel DILI biomarkers in retrospective Pro Euro DILI cohort

Code: AC00031. PIs: Raul J. Andrade; Guru Aithal. Co-Investigators: MI Lucena

Budget: 19.415,31 . Years: 07.05.2020-31.12.2020

Research Project Agreement between PREGLEM S.A & RAUL J. ANDRADE (University of Malaga) entitled: "Ulipristal: analysis of the potential associated risk of liver injury". Project n°: 8.06/5.34.5133. Budget: 46900. Years: 2018. Project n°: 806/34.5288. Years: 2019-2021. Budget: 80.000

Research Project Agreement between Schwabe GmbH and Co. KG & RAUL J. ANDRADE (University of Malaga) entitled: "Liver injury by herbal dietary supplements or medicinal products". Project N°: 701079.01.409. Budget: 46.550. Years: 2019

GILEAD SCIENCES EUROPE LTD MASTER SERVICES AGREEMENT

Collaboration with Gilead Science Europe on the co-morbidities and concomitant medication usage in Chronic Hepatitis C. Year: 2015

Collaboration Agreement between the Spanish Foundation for Functional Gastrointestinal Disorders (FEAD), the University of Malaga and D^a Maria Isabel Lucena Gonzalez and D^a Mercedes Robles-Diaz for a research. Project: "Support of a multicenter and multidisciplinary network of hepatotoxicity induced with some herbal products in Ibero-America.

Researchers: Mercedes ROBLES DIAZ; M^a Isabel Lucena; Raul J. Andrade Bellido; Andres

Gonzalez; Inmaculada Medina; Ana F. Gonzalez; Fernando Bessone; Nelia Hernandez; Milagros Davalos; Marco Arrese; Nahum Mendez; Raymundo Parana

Amount: 6.000 -Years: 2014

COLLABORATION AGREEMENT BETWEEN BIOIBERICA S.A. AND THE UNIVERSITY OF MALAGA THROUGH THE PHARMACOLOGY AND MEDICINE DEPARTMENT.

Principal investigators: M^a Isabel Lucena Gonzalez, Raul J Andrade Bellido

Funding agency: BIOIBERICA S.A

Years: May 2013 - May 2016

INTERNATIONAL SAE CONSORTIUM LTD.

International Consortium on Drug Hypersensitivity (IDILIC) ("Network")

Genome wide analysis and sequencing on drugs-induced liver injury

Principal investigators: M I Lucena, R J Andrade, C Stephens

Years: 2010-2012 - Amount: 227.000

NATIONAL RESEARCH NETWORKS:

Principal Investigator of the CIBERehd (Networked Biomedical Research Center)
(<http://www.ciberisciii.es>)

IBIMA (Malaga Institute of Biomedical Research) (www.ibima.eu)

Member of the scientific committee of the Andalusian Society of Gastroenterology (www.sapd.es)

Expert of the Spanish Medicines Agency in the Evaluation of liver safety of drugs
(<http://www.aemps.gob.es>)

Member of the scientific committee of the Spanish Society for the Study of the Liver (www.aeeh.es)

Member of the scientific committee of the Spanish Society of Gastroenterology (www.sepd.es)

Memberships

NATIONAL RESEARCH NETWORKS:

Principal Investigator of the CIBERehd (Networked Biomedical Research Center)
(<http://www.ciberisciii.es>)

IBIMA (Malaga Institute of Biomedical Research) (www.ibima.eu)

Member of the scientific committee of the Andalusian Society of Gastroenterology (www.sapd.es)

Expert of the Spanish Medicines Agency in the Evaluation of liver safety of drugs
(<http://www.aemps.gob.es>)

Member of the scientific committee of the Spanish Society for the Study of the Liver (www.aeeh.es)

Member of the scientific committee of the Spanish Society of Gastroenterology (www.sepd.es)

MEMBERSHIP IN INTERNATIONAL PROFESSIONAL ORGANIZATIONS:

European Association for the Study of Liver Diseases

American Association for the Study of the Liver (AASLD)

Member of the European Network of Centres for Pharmacoepidemiology and Pharmacovigilance (ENCePP) of the European Medicines Agency (EMA)

Member of the European Clinical Research Infrastructures Network (ECRIN).

International Serious Adverse Event Consortium.

International Consortium on Drug Hypersensitivity (IDILIC) ("Network")

SAFE-T Consortium (Safer and Faster Evidence-based Translation) of the European Union's Innovative Medicines Initiative (<http://www.imi-safe-t.eu/>)

EDITORIAL ASSIGNMENTS:

Editorial Board of Current Drug Safety, World Journal of Gastroenterology, International Journal of Clinical Pharmacology and Therapeutics, Hepatology, Gastroenterology and Hepatology

External referee of : Gastroenterology, Hepatology, Journal of Hepatology, Alimentary Pharmacology & Therapeutics, Lancet, Drug Safety, Clinical Infectious Diseases among others high rated journals, The Lancet, Hepatology...

Associate editor of Liver International (2014)

Full member of the following societies: Sociedad Andaluza de Patologia Digestiva, Sociedad Espanola de Patologia Digestiva, Asociacion Espanola para el Estudio del Hgado, European Association for the Study of the Liver, American Association for the Study of Liver Disease

Member of the International Serious Adverse Event Consortium (ISAEC)

Member of the steering committee of the Standardization Phenotype Project of the ISAEC

Leader investigator of the Spanish Drug Induced Liver Injury (DILI) Registry a network intended to capture cases of hepatotoxicity and to perform phenotypic and genetic studies in the subject.

Member of the steering committee of the Group of Special Interest in Hepatotoxicity patronised by the American Association for the Study of Liver Diseases.

Speaker and moderator in several regional as well as national and international meetings and symposia.

Member of the editorial board of:

-Current Drug Safety.

-World Journal of Gastroenterology.

-International Journal of Clinical Pharmacology and Therapeutics.

-Hepatology

-Gastroenterology and Hepatology

External referee of : Gastroenterology, Hepatology, Journal of Hepatology, Alimentary Pharmacology & Therapeutics, Lancet, Drug Safety, Clinical Infectious Diseases among others high rated journals, The Lancet, Hepatology...

Member of the working team on the Cholestatic and Drug-induced Liver Disease section of the EASL HEPAMAP project.

Guest of Honour of the Medical Sciences Faculty - National University of Rosario, Argentine.

Part of the Reviewing board for the EASL International Liver Congress

CATEGORY: Alcoholic liver disease and Drug induced liver disease.

Our Group is part of the steering committee of important international initiatives in Hepatotoxicity: Phenotyping Standardisation Project in Hepatotoxicity - and Hepatotoxicity Special Interest Group (SIG) of the American Association for the Study of Liver Diseases (AASLD).

Other Relevant Information

Raul J. Andrade is Professor of Medicine and Director of the Department of Medicine at the University of Malaga. Director of the Unidad de Gestion Clinica of Ap Digestivo, University Hospital of Malaga. Founder and director of the Spanish Drug Induced Liver Injury (DILI) Registry (www.spanishdili.uma.es)-the first network specialized in the study of Drug Induced Liver Injury- and of the Spanish Latin-American DILI Network and the recently set-up Prospective European DILI Registry awarded by the European Association for the Study of the Liver (EASL). Appointed by the EASL as Chairman of the Clinical Practice Guidelines Council responsible for writing a new CPG on Drug Induced Liver Injury 2016. Chair of CIOMS (Council for International Organizations of Medical Sciences) working group on DILI 2017. Chair COST ACTION CA17112. Principal investigator of CIBERehd group. Expert of the European Medicines Agency (EMA) and the Spanish Medicines Agency in the Evaluation of liver safety of drugs. Member of the steering committee of the Group of Special Interest in Hepatotoxicity (AASLD). He is member of the expert panel of the EFSA (European Food Safety Authority) since 2016. Member of the Reviewing board for the EASL International Liver Congress (2013-2016). We are partner of the H2020 JTI IMI TRANSBIOLINE project, and the COST grant proposal Prospective European Drug-Induced Liver Injury Network. Invited speaker in international meetings such as: Gordon Research Conference, Maine, USA (2008); NIH Workshop (Maryland, USA 2008); EASL Postgraduate course Cholestatic disease of the liver and bile ducts (Berlin, 2011); EASL-IASL JOINT SYMPOSIUM (London 2014); Co-Chair Meet-The Professor Lunch at the AASLD (Boston, 2014); EASL/AASLD Monothematic Conference on Autoimmune Hepatitis (London, 2015); EASL Monothematic Conference on NASH (Riga, Latvia 2016); AASLD Liver Meeting (Boston, 2016); 26th Conference of the APASL (Shanghai 2017); EASL Monothematic Conference Cholangiocytes in health and Disease: from basic Science to novel treatments (Oslo, Norway 2017). Expert panel member Breakfast Morning rounds & Clinical Practice Guidelines session @ EASL Meeting 2018 (Paris). EASL-INASL Symposium on DILI (Delhi 2018); FIP World Congress (Glasgow 2018); China-CIOMS session meeting on DILIN (Beijing & Chongqing 2018); Special Interest Group in Hepatotoxicity Meeting @ AASLD Liver Meeting (San Francisco, 2018); Expert Panel Member Breakfast morning rounds; Co-Chair & Speaker EASL-ALEH session @ EASL Meeting (Vienna 2019). FDA Liver Seminars (Maryland 2019). "DILI: update and practical management" at the 4th Swiss Hepatology Postgraduate Course (Vevey, 2019). 5th Sino-America International Symposium on Drug-Induced Liver Injury and 6th National Conference in Drug-Induced Liver Injury (Shanghai 2019). AASLD SIG Hepatotoxicity webinar "Drug-Induced Liver Injury in older people: where do we stand?" 2020. EASL Postgraduate course "Lifestyle and the Liver" (Session 5: "The risk for the liver of body building and sport performance products") London 2021 (virtual). International Palliative Care Meeting in Liver Diseases. Leiria Portugal 2021. Chair & Speaker of the International Consensus Conference DI-AIH". Nerja (Malaga) 2022. He is Associate editor of Liver International (Q1) and member of the editorial board of: Hepatology (2012-2016) (D1) and Frontiers in Pharmacology (Q1). He ranks 2nd among "Chemical and Drug-Induced Liver Injury" experts worldwide, in the webpage "Expertscape" which provides an objective ranking of researchers and institutions based on their mastery of more than 29,000 biomedical topics. The ranking is performed based on existing publications in Pubmed between 2012-2022. He published over 300 articles in peer-review journals, and 43 book chapters. He has an h-index of 57 and 14164 total citations by 9164 documents. 33 publications were cited more than 100 times and 64 original articles received more than 50 citations. He presented more than 340 communications in International & National Scientific Meetings. In the past 5 years, he has directed 10 PhD thesis included 2 international thesis. Human resources through competitive convocatories: 2 CIBERehd contracts, Reinforcement of research staff in the digestive units of the andalusian Health System (2016-2022), 1 Sara Borrell CD20/00083 (2022) 1 Rio Hortega CM21/00074 (2022), 1 Juan Rodes JR16/00015 (2017), 1 Nicolas Monardes (2020), 5 technicians Garantia Juvenil (2017-2019-2020-2021-2022), 1 IPFIS IF121/0034 (2022).

Guest of Honour of the Medical Sciences Faculty - National University of Rosario, Argentine.

Expert for the SAG CVS meeting on Kynamro. EMA meeting, London, 10 Septiembre, 2012.

Participant of the European Scientific Board Meeting of Aegerion Pharmaceuticals. "European Liver Safety Scientific Advisory Meeting"- Amsterdam, 13 September, 2012.

Expert commentator in the exposition of the oral Works

Module: Hígado, hepatitis tóxica, viral y autoinmune durante la Semana Nacional de Gastroenterología. Organizer: The Mexican Association of Gastroenterology. Merida, Yucatan. Mexico. 17-21 November, 2012

Participation in the Hepamap - EASL Roadmap to Hepatology Research in Europe.

Cholestatic and drug-induced liver disease.

Since 2012. Expert of the European Medicines Agency (EMA) in the Evaluation of liver safety of drugs.

2013. Member of the European Board of Gastroenterology and of the European Board of Hepatology.

2013. Member of the Reviewing board for the EASL International Liver Congress.

CATEGORY: Alcoholic liver disease and Drug induced liver disease.

2014. "Special Section Editor in DILI" in Liver International.